Physician profile
Meredith Carr
NPI 1720634397
$11,997.98
in general payments reported to CMS, 2019-2025
42 companies · $2,303 in 2025
The $2,303 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,550 · 2022: $2,584 · 2023: $3,060 · 2024: $1,502 · 2025: $2,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,406 · Travel and Lodging: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,405.85 |
| Travel and Lodging | $1,458.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,012.35 | 2025 | Inspire |
| Novo Nordisk INC | $1,960.00 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,672.97 | 2021-2025 | |
| Lilly USA, LLC | $794.13 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $699.52 | 2021-2024 | Farxiga, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $576.81 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.95 | 2021-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $397.67 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $392.65 | 2021-2024 | |
| Pfizer INC. | $325.28 | 2021-2024 | |
| Abbott Laboratories | $321.39 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $312.62 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $241.57 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Scilex Pharmaceuticals INC. | $172.49 | 2021-2023 | Ztlido |
| Idorsia Pharmaceuticals US INC | $162.28 | 2022-2024 | Quviviq |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.